Search results for "osteonecrosi"
showing 10 items of 207 documents
Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery : an institution's experience
2020
Background Dentoalveolar surgery is a predisposing factor for medication related osteonecrosis of the jaw (MRONJ). The aim of our study was to evaluate the described surgical procedures to prevent the development of MRONJ after dentoalveolar surgery in patients receiving bisphosphonates. Material and methods In this retrospective study, sixty-three dentoalveolar surgeries were performed on 44 patients taking bisphosphonate in accordance with the treatment procedures we described. The following procedures were applied to patients 1) use of antibiotics 2) performed dentoalveolar surgical procedures 3) fill the socket with leukocyte- and platelet-rich fibrin (L-PRF) 4) post-operative applicati…
Oral squamous cell carcinoma mimicking osteonecrosis of the jaw: a case report
2021
RE: MEDICATION-RELATED OSTEONECROSIS OF THE JAW (MRONJ)
2021
Idiopathic osteonecrosis of the mandible in a 49 healthy male patient: a rare and interesting case report
2019
Comments on “Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus”
2015
Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series
2010
Abstract Purpose To report a case series of patients with the nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw—a form of jaw osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration. Methods Among 332 individuals referred to 5 clinical centers in Europe because of development of jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters. Results The most common clinical feature of nonexposed osteonecrosis was jaw bone pa…
Farmacovigilanza attiva sul ruolo dei farmaci antiangiogenetici nell’osteonecrosi dei mascellari
2013
Farmacovigilanza attiva sul ruolo dei farmaci antiangiogenetici nell’osteonecrosi dei mascellari Ilaria Morreale1, Maria Meli1, Olga Di Fede2, Giuseppina Campisi2, Natale D’Alessandro1 1Centro di consulenza sulle reazioni avverse da farmaci in oncologia della Regione Sicilia – U.O.C. di Farmacologia Clinica e 2Gruppo P.R.O.Ma.B. (Prevenzione e Ricerca sull’Osteonecrosi dei Mascellari da Bisfosfonati) - Settore di Medicina Orale "Valerio Margiotta" - AOUP “P. Giaccone” di Palermo Obiettivi L’uso dei bisfosfonati (BP) in oncologia e anche nell’osteoporosi è stato definitivamente associato ad una complicazione relativamente rara ma grave come l’osteonecrosi dei mascellari (ONJ). La patogenesi …
Raccomandazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione
2013
Osteonecrosis of the jaw prevention in oncological patients: preliminary results from a teledentistry sicilian project
2019
Follow-up of non-exposed ONJ related to bisphosphonate: a two-year study
2015
Aim. Osteonecrosis of the jaw (ONJ) is a serious sideeffect of amine bisphosphonate (NBP) and/or other antiresorptive agents frequently used in the management of osteometabolic and cancer-related condition. The traditional ONJ definition exclude patients who present the non-exposed variant. However, according to recent data, staging and monitoring of ONJ should be closely linked to clinical and radiological manifestation regardless of the presence of bone exposed. The aim of this study was a descriptive analysis of a case series of patients with non-exposed ONJ (exclusively related to NBP) monitoring for two years. Methods. From 2012 to 2014, 16 patient [7 oncological (F/M=3/4; mean age=66,…